CRLF3 Activators
Cytokine Receptor Like Factor 3 (CRLF3) is a protein that is coded by the CRLF3 gene in humans. As its name suggests, it is part of a larger family of proteins known as cytokine receptor-like factors, which are known to be involved in a variety of cellular processes, including cell growth, differentiation, and survival.Cytokines are small proteins that play essential roles in cell signaling and can influence the immune system. Cytokine receptors, including those in the CRLF family, bind to these cytokines to mediate their effects on the body.
Emerging research indicates potential links between CRLF3 and several disease processes. For instance, alterations in the expression or function of CRLF3 have been implicated in certain types of cancer, such as breast cancer, indicating that it might play a role in tumorigenesis and cancer progression.In summary, CRLF3 is a member of the cytokine receptor-like factor family with potential roles in cell signaling and disease processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A potent, reversible, and cell-permeable proteasome inhibitor. It blocks the degradation of ubiquitinated proteins, potentially enhancing NEURL2 activity by stabilizing its substrates. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
An irreversible proteasome inhibitor. By inhibiting proteasome activity, it could indirectly modulate NEURL2-mediated ubiquitination processes. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective and potent proteasome inhibitor. It blocks the degradation of ubiquitin-proteasome pathway substrates, potentially affecting NEURL2 activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
An irreversible proteasome inhibitor. It impairs the degradation of ubiquitinated proteins, which may impact NEURL2's role in ubiquitin tagging. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A dipeptide boronic acid and proteasome inhibitor. It targets the ubiquitin-proteasome pathway, potentially influencing NEURL2 activity. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
An oral proteasome inhibitor. It disrupts the degradation pathway of ubiquitinated proteins, potentially altering NEURL2 function. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
A proteasome inhibitor. It affects the turnover of ubiquitinated proteins, potentially impacting NEURL2 activity. | ||||||
JNJ-26481585 | 875320-29-9 | sc-364515 sc-364515A | 5 mg 50 mg | $321.00 $1224.00 | ||
A natural product-based proteasome inhibitor. It could indirectly affect NEURL2 by altering proteasome-mediated protein degradation. | ||||||